Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial …

L Gianni, W Eiermann, V Semiglazov, A Lluch… - The Lancet …, 2014 - thelancet.com
Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH)
trial in women with HER2-positive locally advanced or inflammatory breast cancer …

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial …

L Gianni, W Eiermann, V Semiglazov… - The Lancet …, 2014 - pubmed.ncbi.nlm.nih.gov
Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH)
trial in women with HER2-positive locally advanced or inflammatory breast cancer …

[PDF][PDF] Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority …

L Gianni, W Eiermann, V Semiglazov, A Lluch… - 2014 - researchgate.net
Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH)
trial in women with HER2-positive locally advanced or inflammatory breast cancer …

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial …

L Gianni, W Eiermann, V Semiglazov, A Lluch… - Lancet Oncol, 2014 - thelancet.com
Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH)
trial in women with HER2‑positive locally advanced or inflammatory breast cancer …

[PDF][PDF] Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority …

L Gianni, W Eiermann, V Semiglazov, A Lluch… - 2014 - academia.edu
Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH)
trial in women with HER2-positive locally advanced or inflammatory breast cancer …

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial …

L Gianni, W Eiermann, V Semiglazov, A Lluch… - The Lancet …, 2014 - infona.pl
In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women
with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant …

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial …

L Gianni, W Eiermann, V Semiglazov, A Lluch… - The Lancet …, 2014 - europepmc.org
Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH)
trial in women with HER2-positive locally advanced or inflammatory breast cancer …

[引用][C] Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority …

L Gianni, W Eiermann, V Semiglazov, A Lluch… - The Lancet …, 2014 - cir.nii.ac.jp
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast
cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel …

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial …

L Gianni, W Eiermann, V Semiglazov, A Lluch… - The Lancet …, 2014 - Elsevier
Background In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH)
trial in women with HER2-positive locally advanced or inflammatory breast cancer …

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial …

L Gianni, M Zambetti, W Eiermann, V Semiglazov… - The Lancet …, 2014 - elibrary.ru
The trial was sponsored and funded by F Hoffmann-La Roche and was designed by LG in
collaboration with the sponsor. The sponsor had no role in data analysis, but employees of F …